"Promising Results: Merck-Moderna Vaccine Reduces Skin Cancer Recurrence by 50%"

A personalized vaccine developed by Merck and Moderna has shown promising results in preventing the recurrence of severe skin cancer for three years, according to a study. Patients who received the vaccine along with Merck's cancer drug Keytruda were 49% less likely to die or have their cancer return compared to those who received Keytruda alone. The findings are significant for Moderna, as it seeks to expand the use of its messenger RNA technology beyond COVID-19. The vaccine, which involves analyzing the genetic sequence of each patient's tumor to create a personalized therapy, could potentially be approved and launched as early as 2025.